IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents strong financial performance with revenue and EPS growth, a consistent gross margin, and increased domestic sales. The Q&A section reveals a solid backlog, positive sentiment towards the new product launch, and potential market expansion. However, international sales declined, and management was vague about the quantitative impact of the new pump. Despite these concerns, the overall sentiment is positive due to strong earnings, optimistic guidance, and a dividend announcement, suggesting a likely stock price increase in the next two weeks.
Key Financial Performance
Revenue $20.4 million for Q2 2025, a 14% increase from $17.9 million in Q2 2024. Growth driven by strong performance across all product lines, particularly MRI compatible IV infusion pump systems and patient vital signs monitoring systems.
Gross Profit $16 million for Q2 2025, a 14% increase from $14 million in Q2 2024. Gross margin remained consistent at 78%, supported by increased overhead absorption due to inventory buildup ahead of the new facility's opening.
GAAP Diluted Earnings Per Share $0.45 for Q2 2025, an 18% increase from $0.38 in Q2 2024. Growth attributed to strong revenue performance and operational efficiency.
Non-GAAP Diluted Earnings Per Share $0.49 for Q2 2025, a 17% increase from $0.42 in Q2 2024, excluding $0.6 million of stock-based compensation expense net of tax.
Domestic Sales $18.2 million for Q2 2025, an 18% increase from Q2 2024. Growth driven by strong domestic demand for MRI compatible IV infusion pump systems and patient monitoring systems.
International Sales $2.2 million for Q2 2025, a 9% decrease from Q2 2024. Decline attributed to weaker international demand.
Operating Expenses $9.2 million for Q2 2025, a 9% increase from $8.4 million in Q2 2024. Increase driven by higher sales and marketing expenses and modest increases in general and administrative costs.
Income from Operations $6.8 million for Q2 2025, a 21% increase from $5.6 million in Q2 2024. Growth driven by strong revenue performance and controlled operating expenses.
Net Income $5.8 million for Q2 2025, an 18% increase from $4.9 million in Q2 2024. Growth attributed to strong revenue and operational efficiency.
Cash and Cash Equivalents $53 million at the end of Q2 2025, up from $52.2 million at year-end 2024. Increase driven by strong cash flow from operations.
Cash Flow from Operations $7.7 million for Q2 2025, a 17% increase from $6.6 million in Q2 2024. Growth attributed to strong revenue performance and operational efficiency.
Free Cash Flow $4.9 million for Q2 2025, reflecting capital expenditures of $6.7 million year-to-date, primarily related to the new facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA clearance of 3870 IV pump systems: The FDA cleared the new 3870 IV pump systems for distribution, marking a significant milestone for the company. This new pump is expected to drive substantial sales growth, replacing older models and leveraging 20 years of technological advancements.
Performance of 3860 MRI IV pump: The 3860 MRI IV pump continued to excel, leading pump shipments in Q2 2025.
MRI patient monitor growth: Shipments of MRI patient monitors grew by 9% in Q2 2025, with strong bookings indicating alignment with 2025 sales plans.
Domestic market expansion: The company plans to target replacing over 6,200 older 3860 pump channels in the U.S. market, aiming to add 1,000 replacement sales annually starting in 2026, with further growth expected in subsequent years.
Revenue growth projection: Domestic pump device revenue is projected to grow from $28 million in 2025 to nearly $50 million, supported by increased sales of the new 3870 pump channels and disposables.
Facility transition: The company moved into a new facility, which caused short-term operational inefficiencies but is expected to support future growth.
Increased sales and marketing expenses: Operating expenses rose by 9% due to higher sales and marketing costs to support growth.
Revenue target and growth strategy: The company aims to surpass a $100 million revenue run rate by 2026, driven by the new 3870 pump and replacement sales strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs and Pre-Tariff Inventories: The company acknowledges that tariffs, particularly Chinese tariffs, have had a small impact so far. However, as pre-tariff inventories dwindle, the measurable impact of tariffs may increase, posing a potential risk to cost management and profitability.
Operational Inefficiencies During Facility Transition: The company anticipates short-lived operational inefficiencies as they transition to a new facility, which could temporarily impact operational performance and financial results.
Decline in International Sales: International sales decreased by 9% in Q2 2025, which could indicate challenges in global market penetration or competition, potentially affecting overall revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q3 2025: The company expects revenue of $20.5 million to $20.9 million, representing 12% to 14% growth over Q3 2024.
Earnings Guidance for Q3 2025: GAAP diluted earnings per share is anticipated to be $0.41 to $0.45, and non-GAAP diluted earnings per share is expected to be $0.45 to $0.49, reflecting 10% to 12% growth over Q3 2024.
Full Year 2025 Revenue Guidance: The company has raised its revenue guidance to $80 million to $82.5 million, up from the prior range of $78 million to $82 million, representing 9% to 13% growth over 2024.
Full Year 2025 Earnings Guidance: GAAP diluted earnings per share is now expected to be $1.60 to $1.70, up from $1.55 to $1.65. Non-GAAP diluted earnings per share is expected to be $1.76 to $1.86, up from $1.71 to $1.81.
Revenue Projections for 2026: The company anticipates achieving a $100 million revenue run rate in 2026, driven by increased sales of the new 3870 IV pump systems and replacement of older 3860 model pumps.
Domestic Pump Device Revenue Growth: The company expects domestic pump device revenue to grow from $28 million in 2025 to nearly $50 million in subsequent years, supported by higher ASPs and increased replacement sales.
Facility Transition Impact: Short-lived operational inefficiencies are anticipated during the facility transition, which may temper Q3 2025 earnings growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Dividend: The company declared a $0.17 per share quarterly dividend for Q3, payable on August 28, 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the composition of the backlog and how you expect 3860 sales to trend before the 3870 launch?
A:The backlog as of June 30 was a record and composed of both pumps and a strong monitoring backlog. This provides good visibility into the second half of the year. The 3860 sales are still trending strong, and the company plans to control the transition to the 3870, with active sales discussions for the new pump starting in December.
Q:How do you think about the cadence of the ramp to $50 million of pump revenue and how it scales through 2026?
A:The company plans to sell a few 3870s in Q4 for feedback purposes, with significant revenue impact starting in Q1 2024. Q1 bookings for pumps are expected to be weak, but revenue will remain strong due to the backlog. Bookings will strengthen in Q2 and accelerate through Q3 and Q4, with the business run rate expected to surpass $100 million by the end of 2026.
Q:Do you think the functionality and improvements of the 3870 could expand the overall market and demand in the pump area?
A:The new pump, with its modern and user-friendly interface, addresses usability issues of the older pump. This could accelerate adoption among those who were hesitant before, potentially expanding the market. However, this upside has not been factored into the current projections.
Q:Is there an ASP increase for the new pump, and will it impact gross margins?
A:The ASP for the new pump is expected to be around 12% higher than the existing pump. This increase should positively impact gross margins and potentially operating margins as well.
Q:What is the timing for fulfilling the backlog from order to delivery?
A:Monitor backlog fulfillment takes about 4-5 weeks, while pump backlog fulfillment takes about 5-6 months. The company is leveraging this backlog to maintain revenue during the transition to the new pump.
Q:Will customers expecting pumps this year be motivated to upgrade to the new pump?
A:No, customers receiving pumps this year are not expected to upgrade. The company plans to deliver 40-50 new pumps to a limited number of facilities for feedback and refinement purposes before a broader rollout.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on how the 3870's improvements might quantitatively expand the market, stating only that it could accelerate adoption among hesitant users. Additionally, while they mentioned a 12% ASP increase for the new pump, they did not provide detailed projections on how this would impact gross or operating margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP pump
CEO President
CFO Corporate
CORPORATION Mr
Capital Partners
Chairman CEO
Conference Instructions
Corporate Secretary
Division Conference
Division Jason
ET Welcome
FDA IV
FDA action
Founder Chairman
Frank Takkinen
Glenn
IRADIMED result
LLC Research
MRI IV
Research Division
base
effect
market
niche
number
pump channel
revenue
run rate
shipment MRI
stock
tariff impact
unit year
IRMD Transcript
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call provided positive financial results, with a 12% revenue increase and improved net income and EPS. However, the slight decrease in gross margin and increased operating expenses may temper enthusiasm. The lack of strategic, operational, and risk discussions, combined with no additional insights from the Q&A, suggests limited new information to drive a strong stock price movement. With no market cap data, a neutral sentiment is appropriate, as positive financials are offset by operational cost increases and unchanged strategic outlook.
IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call summary and Q&A reveal strong financial performance with increased EPS and revenue, stable gross margins, and positive cash flow. The market feedback on the new 3870 MRI IV pump system is very positive, with additional orders already placed. The company also raised its financial guidance for the year, indicating confidence in future growth. These factors suggest a positive sentiment that will likely lead to a stock price increase of 2% to 8% over the next two weeks.
IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript
Positive11-3
The company reported strong financial performance with a 16% revenue increase and improved gross margins. Despite higher operational costs, the raised revenue and earnings guidance for 2025 and 2026, along with strategic growth plans, indicate optimism. The Q&A highlighted stable pricing and sufficient inventory, with plans for international expansion. The dividend declaration also supports a positive sentiment. However, concerns about operational costs and tax rate increases temper the outlook slightly. Overall, the sentiment is positive due to strong earnings, raised guidance, and strategic initiatives.
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
Positive8-1
The earnings call presents strong financial performance with revenue and EPS growth, a consistent gross margin, and increased domestic sales. The Q&A section reveals a solid backlog, positive sentiment towards the new product launch, and potential market expansion. However, international sales declined, and management was vague about the quantitative impact of the new pump. Despite these concerns, the overall sentiment is positive due to strong earnings, optimistic guidance, and a dividend announcement, suggesting a likely stock price increase in the next two weeks.
IRMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
